Zoetis Inc. (ZTS) — Q2 2026 Earnings Preview

1. Earnings Preview

Key Takeaway: The setup is cautiously constructive but asymmetric to the downside — consensus has been reset to near-zero Q2 growth (mirroring Q1's 0% organic print), the bar is low, but the single biggest swing factor is whether U.S. companion animal demand shows any sequential improvement or continues to deteriorate.

Heading into Q2 2026, ZTS faces a reset bar after the Q1 miss and guidance cut, with consensus now modeling roughly flat organic operational growth for the quarter — a level management itself telegraphed at Stifel (May 28) when CFO Wetteny Joseph described Q2 as "highly reflective of Q1 from a growth rate perspective." Management's posture has shifted to explicitly cautious: macro and competitive headwinds are expected to persist through the full year, vet clinic visits remain negative (IDXX guided −1.5% for H2), and the meaningful inflection to positive growth is back-weighted to H2 on easier comps rather than any underlying demand recovery. Estimate revisions have tracked guidance lower — Q2 revenue consensus of ~$2.50B and adj. EPS of ~$1.86 are both modestly below the post-Q1 baseline, suggesting the Street has absorbed the guidance cut but has not yet priced in further deterioration. The stock has declined ~15% since the Q1 print (to ~$74), massively underperforming XBI (+14.5%) and SPY (+5.2%), and now trades at ~19–20x forward earnings — well below its 10-year average of ~32x — suggesting the market has priced in a prolonged trough but not a structural break. The key wildcard is peer read-through from ELAN's Q2 2026 print (reported today, August 5): Elanco reported 8% organic growth and raised full-year guidance, citing a strong market rebound from March onward and resilient pet owner spending — a meaningfully more constructive read on the same end market that ZTS described as persistently challenged, creating a potential positive surprise if ZTS's U.S. companion animal trends similarly inflected in Q2.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus sets a low bar for Q2 2026 — near-zero organic growth is already embedded in estimates. Key Dermatology revenue is the bigger swing factor: at $445M consensus vs. $347M actual in Q1, the implied sequential ramp is steep and depends on whether competitive dynamics (Zenrelia, Numelvi) have stabilized.

Table 1 — Q2 2026 Current Quarter Snapshot

Source: Visible Alpha Consensus and Actuals Data. All consensus figures as of August 5, 2026. Guidance from Q1 2026 earnings call (May 7, 2026) and Stifel/William Blair conferences (May–June 2026).

Table 2 — Beat/Miss History (Last 8 Quarters, Top 2 KPIs)

Top KPI #1: Total Revenue

Top KPI #2: Adj. Diluted EPS

Pattern: ZTS had a strong 6-quarter beat streak through Q3 2025 before two consecutive misses in Q4 2025 and Q1 2026, both driven by U.S. companion animal weakness that exceeded management's own expectations — the bar has now been reset materially lower heading into Q2 2026. Source: Visible Alpha Consensus and Actuals Data.

3. Guidance & Commentary Evolution

Key Takeaway: Guidance was cut at Q1 2026 earnings (May 7) and has not been formally revised since, but management commentary at Stifel (May 28) and William Blair (June 2) reinforced a cautious tone — Q2 organic growth expected to mirror Q1's near-zero performance, with the meaningful inflection to positive growth back-weighted to H2 on easier comps.

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimates have tracked guidance lower since the Q1 print, with Q2 revenue and EPS consensus both modestly below the post-earnings baseline — the gap is small, suggesting the Street has absorbed the guidance cut but has not built in further cushion. FY 2026 estimates sit near the low end of the revised guidance range, implying limited room for another miss.

Estimates have been remarkably stable since the Q1 print, moving less than 1% in either direction — suggesting the Street has fully digested the guidance cut and is waiting for Q2 results to determine whether the H2 recovery thesis is credible. The key risk is that consensus for Key Dermatology ($445M in Q2 vs. $347M in Q1) embeds a steep sequential ramp that may not materialize if competitive dynamics remain intense.

Source: Visible Alpha Consensus and Actuals Data.

5. Stock Performance

Key Takeaway: ZTS has declined ~15% since the Q1 2026 earnings print (May 7), dramatically underperforming both XBI (+14.5%) and SPY (+5.2%) — the underperformance is driven by multiple compression and negative estimate revisions, not sector-wide weakness, as biotech has rallied sharply in the same period. The stock now trades at ~19–20x forward earnings, well below its 10-year average of ~32x, suggesting the market is pricing in a prolonged trough.

ZTS vs. XBI (SPDR S&P Biotech ETF) vs. S&P 500 (SPY) — Indexed to 100 at Q1 2026 Earnings (May 7, 2026). Source: Stock Price Data.

• ZTS: −14.8% since Q1 earnings (May 7 close: $87.31 → Aug 5: $74.39). Steady decline with no meaningful recovery, reflecting persistent negative sentiment on U.S. companion animal outlook.
• XBI: +14.5% over the same period — biotech sector rallied broadly, making ZTS's underperformance entirely idiosyncratic rather than sector-driven.
• SPY: +5.2% — broad market strength further highlights ZTS's relative weakness.
• Key events: Stifel Conference (May 28) and William Blair Conference (June 2) reinforced cautious tone; Stifel PT cut to $85 (June 26) and HSBC PT cut to $95 (July 6) added further pressure. Analyst consensus has shifted to "Hold" (8 Buy / 8 Hold / 1 Sell) with average PT of ~$123, implying significant upside from current levels but reflecting uncertainty on recovery timing.

6. Peer Commentaries — Read-Through for ZTS Q2 2026

Key Takeaway: Peer commentary since May 7, 2026 presents a meaningfully more constructive picture of the animal health market than ZTS's own guidance implies — Elanco (ELAN) reported 8% organic growth in Q2 and raised guidance, IDXX delivered double-digit diagnostics growth, and Chewy flagged macro pressure but continued share gains. The divergence between ELAN's bullish read and ZTS's cautious posture is the most important read-through heading into the print.

Elanco (ELAN) — Q2 2026 Earnings (August 5, 2026) — MOST RELEVANT READ-THROUGH

Implication for ZTS: ELAN's Q2 beat and raised guidance is the single most important read-through for ZTS. Elanco operates in the same U.S. companion animal market (dermatology, parasiticides) and reported 8% organic constant currency growth, outperforming the high end of guidance on revenue, EBITDA, and EPS. If ZTS's end markets were as challenged as Q1 guidance implied, ELAN would not have delivered this result.

• Market rebound confirmed: ELAN confirmed a "strong market rebound starting in March" after a weather-related Q1 speed bump, with the U.S. pet health industry growing mid-single digits for the trailing four quarters through Q1. This directly contradicts ZTS's Q1 characterization of persistent macro deterioration and suggests Q2 may have seen sequential improvement.
• Dermatology market growing, not contracting: ELAN's Zenrelia (JAK inhibitor) reached blockbuster status and June was its largest month ever, with U.S. penetration at ~18,000 clinics (>60% of total). Critically, ELAN described the global derm market as "$2.2 billion and growing" — suggesting the market is expanding even as ZTS loses share. Befrena (IL-31 mAb, direct Cytopoint competitor) soft-launched in May with demand "double the size of expectations." This is a direct competitive headwind for ZTS's Cytopoint franchise in Q2.
• Parasiticide market growing low-to-mid single digits in U.S.: ELAN's Credelio Quattro gained 4 share points in Q2 (on top of 3 points in Q1), with June as its largest month ever. ELAN guided the U.S. broad-spectrum parasiticide market to grow low-to-mid single digits — a more constructive read than ZTS's Q1 characterization of market contraction.
• Pet owner spending resilient: ELAN's own survey (end of May) showed 95% of pet owners would not cut spending on pet health, and 90% expect to maintain or increase spending. Vet channel revenue was up low single digits year-to-date. This is more constructive than ZTS's Q1 commentary on broad-based price sensitivity.
• Vet visits still negative but improving: ELAN explicitly stated its guidance "does not assume a recovery in vet clinic volumes" — yet still delivered 8% organic growth, demonstrating that omnichannel and innovation can offset visit headwinds. ZTS's vet-channel-heavy model is more exposed to visit declines.
• Pricing rational, no race to the bottom: ELAN took its largest price increase in the U.S. vet channel in five years at the start of 2026, and price accelerated in Q2. This is consistent with ZTS's strategy of not competing on price, and suggests the competitive environment may be less destructive than feared.
• Full-year guidance raised: ELAN raised FY 2026 organic constant currency growth guidance to 6–7% (from 5–7%), raised EBITDA guidance to $1.01–1.035B (13% growth at midpoint), and raised adj. EPS to $1.10–1.16 (20% growth at midpoint). This is a strong positive read-through for animal health sector demand.

Elanco (ELAN) — Stifel Jaws & Paws Conference (May 27, 2026)

Implication for ZTS: ELAN's pre-Q2 conference commentary was already more constructive than ZTS's Q1 guidance, flagging a March/April/May rebound and describing the pet consumer as "as durable as I've seen."

• Market rebound in March/April/May: ELAN CEO described a "strong rebound" in March, April, and May after Q1 weather headwinds, with dispensed products for both derm and parasiticide markets showing positive growth. This is a direct positive read-through for ZTS's Q2 trends.
• Derm market growing double digits: ELAN described the derm market as "$2 billion growing double digit" — if the overall market is growing double digits, ZTS's share losses may be partially offset by market expansion, which was the key missing element in Q1.
• Parasiticide market grew 27% in 2025, expected to surpass $2B: The broad-spectrum endecto market grew 27% in 2025 and is expected to continue growing. ELAN's Quattro gained 3 share points since Q4 2025. This is a headwind for ZTS's Simparica Trio but confirms the overall market is healthy.
• No pricing race to the bottom: ELAN confirmed pricing is not being used as a lever to capture share, with the market at "record high pricing" and ELAN guiding for strong pricing in H2. This supports ZTS's strategy of maintaining premium pricing.
• Guidance does not assume vet visit recovery: ELAN's H2 guidance for U.S. Pet Health of "high single digits to low double digits" does not assume a recovery in vet clinic volumes — suggesting innovation and omnichannel can drive growth even in a soft visit environment.

Elanco (ELAN) — William Blair Growth Stock Conference (June 2, 2026)

Implication for ZTS: ELAN's William Blair commentary reinforced the constructive market view and provided specific data points on vet clinic dynamics and pet owner spending that are relevant read-throughs for ZTS.

• Pet owner spending resilient despite macro: ELAN CEO stated "willingness to spend continues to be very high" and cited survey data showing "almost 90% of pet parents said they are not going to spend less on their pets care going forward." This is more constructive than ZTS's Q1 characterization of broad-based price sensitivity across all demographics.
• Corporate clinic growth accelerating: ELAN's corporate clinic business grew 12% in Q1 2026 (>2x the average U.S. Pet Health growth rate), and ELAN grew with 90% of corporate partners in 2025 (vs. only 13% in 2024). ZTS has historically been strong in corporate clinics — if the corporate channel is recovering, this is a positive read-through.
• Derm market $1.3B with strong growth: ELAN described the U.S. derm market as "$1.3 billion with strong growth," with Zenrelia in over 50% of U.S. clinics and gaining 5 share points from Q4 to Q1. The market is growing even as ZTS loses share, which is the key cushion for ZTS's derm franchise.
• Broad-spectrum parasiticide market grew 25% in 2025: ELAN cited the broad-spectrum endecto market at "$1.5 billion and grew 25% in 2025" and continuing to grow in 2026. This is a positive market backdrop for ZTS's Simparica Trio, even as ELAN's Quattro gains share.
• Market expected to grow low-to-mid single digits in 2026: ELAN guided the overall U.S. pet health market to "grow low single digits to mid-single digits this year" — if correct, ZTS's near-zero Q2 guidance implies continued share loss rather than market contraction.

IDEXX Laboratories (IDXX) — Q2 2026 Earnings (August 4, 2026)

Implication for ZTS: IDXX's Q2 beat (10% revenue growth, 10.3% organic CAG diagnostics recurring revenue growth) confirms that the animal health sector is not uniformly weak — innovation-driven companies are outperforming. IDXX's vet visit data provides the most granular read on clinic traffic trends.

• U.S. same-store clinical visits declined 1.3% in Q2: IDXX reported U.S. same-store clinical visits down ~1.3% in Q2 2026, "largely on track with previous expectations." Wellness visits were down below 3% YoY, while non-wellness visits showed modest growth. For H2 2026, IDXX anticipates U.S. clinical visit declines of approximately 1.5% — still negative but stable, not accelerating. This is a key data point for ZTS's companion animal volume outlook.
• Aging pet population driving green shoots: IDXX noted "green shoots of growth in dogs over 5" for three consecutive quarters, with Q1 2026 seeing growth in both well and non-well dogs. This aging cohort dynamic is a positive tailwind for ZTS's chronic disease franchises (OA pain, dermatology) as older pets require more care.
• Diagnostics growing strongly despite visit headwinds: IDXX delivered 10.3% organic CAG diagnostics recurring revenue growth in Q2, with a ~1,100 bps premium to U.S. clinical visit growth. This confirms that diagnostic intensity per visit is rising — a positive read-through for ZTS's diagnostics segment, which grew 10% in Q1.
• Full-year guidance raised: IDXX raised FY 2026 revenue guidance to $4,700–$4,745M (9.1–10.3% reported growth) and EPS to $14.69–$14.94 (13–15% comparable growth). This is a strong positive read-through for animal health sector demand.
• No significant differences across corporate vs. independent practices: IDXX noted it does not observe significant differences in visit trends across different parts of the country or between corporate and independent practices — suggesting the corporate clinic weakness ZTS flagged in Q1 may be stabilizing.

IDEXX Laboratories (IDXX) — Stifel Jaws & Paws Conference (May 27, 2026)

Implication for ZTS: IDXX's pre-Q2 conference commentary provided early positive signals on the aging pet population and innovation-driven growth that are relevant for ZTS's chronic disease franchises.

• Green shoots in dogs over 5 for 3 consecutive quarters: IDXX CEO highlighted that the pandemic-era pet adoption cohort is aging, with dogs over 5 showing growth for three consecutive quarters. In Q1 2026, this growth was seen in both well and non-well dogs — a positive leading indicator for ZTS's OA pain (Librela) and dermatology franchises, which skew toward older pets.
• Visit quality improving even as volume declines: IDXX noted that visits occurring are of "even more quality from an overall care perspective" with higher diagnostic utilization. This supports ZTS's thesis that per-visit revenue is rising even as visit volumes decline.
• IDXX modestly adjusted visit outlook from −2% to −1.5%: IDXX revised its full-year U.S. clinical visit assumption from −2% to −1.5%, reflecting the positive aging pet signals. This is a modest improvement in the visit outlook that could benefit ZTS's companion animal volume trends in Q2.
• Long-run growth trends "incredibly durable": IDXX CEO described long-run animal health growth trends as "incredibly durable," driven by the deepening human-animal bond across younger generations. This supports the long-term bull case for ZTS even as near-term headwinds persist.

Chewy (CHWY) — Q1 FY2026 Earnings (June 10, 2026)

Implication for ZTS: Chewy's Q1 results (fiscal Q1 ending ~May 2026) confirmed macro pressure on discretionary pet spending but showed continued share gains and resilient recurring/health categories — a mixed but broadly consistent read with ZTS's Q1 characterization.

• Consumer environment weakened in latter part of the quarter: Chewy noted the consumer environment "weakened in the latter parts of the quarter" and has become "incrementally more challenged" since the start of fiscal 2026. Consumers are "growing more discerning, driven in part by elevated fuel prices and broader macroeconomic pressures." This is consistent with ZTS's Q1 commentary on broad-based pet owner price sensitivity.
• Pressure on premiumization and discretionary attach: Chewy flagged "modest pressure on premiumization and product attach rates" with the pace of discretionary attachment running below expectations. This is a negative read-through for ZTS's premium companion animal products (Apoquel, Cytopoint) where price sensitivity is already a headwind.
• Recurring/health categories remain strong: Chewy noted that "consumables and health care categories that are recurring in nature, fueled by the Autoship flywheel continue to be super strong." This is a positive read-through for ZTS's chronic disease franchises (OA pain, dermatology) where compliance and recurring treatment are key.
• Pressures are macro-driven, not structural: Chewy expressed confidence that "the pressures that we're seeing are primarily macro related" based on continued share gains, strong branded searches, and healthy spend cohort behavior in recurring categories. This supports ZTS's thesis that the current headwinds are cyclical rather than structural.
• Q2 outlook: stable macro assumed: Chewy guided Q2 net sales of $3.30–$3.33B (6–7% YoY growth), assuming the current operating environment "remains generally stable with what we experienced exiting the first quarter." This implies no meaningful improvement in the macro environment for ZTS's Q2 either.

Peer Read-Through Summary Table

7. Material News & Developments

Key Takeaway: The most important development since Q1 earnings is Elanco's Q2 2026 beat and raised guidance (reported today), which suggests the U.S. animal health market recovered more than ZTS's cautious guidance implied — a potential positive catalyst for ZTS's Q2 print. The wave of analyst price target cuts post-Q1 has already been absorbed by the stock.

• August 5, 2026 — ELAN Q2 2026 Earnings Beat & Guidance Raise (MOST MATERIAL): Elanco reported 8% organic constant currency growth in Q2, outperforming the high end of guidance on revenue, EBITDA, and EPS. Raised FY 2026 organic growth guidance to 6–7% (from 5–7%). Confirmed strong market rebound from March onward, resilient pet owner spending, and growing derm and parasiticide markets. Implication: Most constructive read-through for ZTS Q2 — if the market recovered as ELAN suggests, ZTS's near-zero Q2 guidance may prove conservative.
• August 4, 2026 — IDXX Q2 2026 Earnings Beat & Guidance Raise: IDEXX reported ~10% revenue growth and raised FY 2026 guidance. U.S. same-store clinical visits declined 1.3% in Q2 (stable vs. prior quarters). Aging pet cohort driving green shoots in dogs 5+. Implication: Confirms animal health sector is not uniformly weak; visit trends stable rather than deteriorating.
• June 25, 2026 — ZTS Announces Q2 2026 Earnings Webcast Date: Zoetis announced it will host a webcast and conference call for Q2 2026 financial results. Confirms earnings are imminent. Implication: Q2 2026 results expected in early August 2026.
• July 6, 2026 — HSBC Cuts Price Target from $140 to $95 (Buy): HSBC maintained Buy rating but cut PT by 32% to $95, reflecting deteriorating near-term outlook. Implication: Even bulls are resetting expectations; $95 PT implies limited near-term upside from current ~$74 levels.
• July 1, 2026 — Barclays Cuts Price Target from $136 to $85 (Equal Weight): Barclays reduced PT to $85, near current trading levels, reflecting continued caution on U.S. companion animal recovery timeline. Implication: Street is not yet willing to look through the trough; recovery evidence needed before PT upgrades.
• June 30, 2026 — TD Cowen Cuts Price Target from $150 to $104 (Buy): TD Cowen maintained Buy but cut PT by 31%, reflecting reset growth expectations. Implication: Bulls maintaining conviction but acknowledging the recovery will take longer than initially expected.
• June 26, 2026 — Stifel Cuts Price Target from $95 to $85 (Hold): Stifel, which had already downgraded to Hold in mid-2025, further reduced PT to $85 — the lowest on the Street. Implication: Most bearish analyst view; $85 PT implies stock is fairly valued at current levels with no recovery premium.
• May 27, 2026 — Argus Research Downgrades to Hold from Buy: Argus cited deteriorating investor confidence and reset growth expectations following the Q1 miss. Implication: Sentiment shift among previously bullish analysts; consensus now evenly split between Buy and Hold.
• May 28, 2026 — Stifel Jaws & Paws Conference: CFO Wetteny Joseph confirmed Q2 organic growth expected to be "highly reflective of Q1" (near-zero), with meaningful inflection back-weighted to H2 on easier comps. Confirmed macro and competitive conditions expected to persist. Implication: Management set a low bar for Q2 — any outperformance would be a positive surprise.
• May 18, 2026 — Citigroup Cuts Price Target from $145 to $112 (Buy): Citi maintained Buy but cut PT by 23%, reflecting the Q1 miss and guidance cut. Implication: Citi remains constructive on the long-term thesis but acknowledges near-term headwinds.
• May 15, 2026 — Morgan Stanley Reiterates Overweight at $115: Morgan Stanley maintained Overweight with $115 PT, one of the more constructive views on the Street. Implication: MS sees the current weakness as cyclical and maintains conviction in the long-term pipeline value.
• May 8, 2026 — UBS Cuts Price Target from $130 to $99 (Neutral): UBS cut PT by 24% to $99 and maintained Neutral, reflecting the Q1 miss and guidance cut. Implication: Neutral camp sees limited near-term catalysts; recovery evidence needed before upgrading.

8. Insider Transaction Activity

Key Takeaway: The most notable signal is three independent directors making open-market purchases totaling ~$1.1M in the days immediately following the Q1 miss (May 11–13, 2026) — a meaningful show of conviction at depressed prices. No open-market sales by executives have been filed in the period, and all executive transactions are routine equity compensation awards (phantom stock units).

Analysis: The cluster of three independent director open-market purchases (totaling ~$806K) in the 4–6 days immediately following the Q1 miss is the most notable insider signal in the period. Directors Damelio, McCallister, and Bisaro all bought at prices in the $66–$77 range, suggesting board-level conviction that the selloff was overdone. No executive open-market sales have been filed since the Q1 print, and all executive transactions are routine equity compensation awards. The absence of insider selling at depressed prices is a mild positive signal. Source: Insider Transaction Data (SEC Form 4).